# Study of TAK-875 in Adults With Type 2 Diabetes and Cardiovascular Disease or Risk Factors for Cardiovascular Disease

Study · id `cardio:ct-nct01609582` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01609582](<https://clinicaltrials.gov/study/NCT01609582>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01609582

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 3207 participants.

## Technical summary

Registry record NCT01609582. Randomized; quadruple masking; primary purpose treatment. Start 2012-06 (registry gives no type); primary completion 2014-05 (actual). Results posted on 2015-08-21.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 3207 participants (enrolled count; ClinicalTrials.gov record NCT01609582, source copy `cardio:ctgov-nct01609582-2015-10-19`, retrieved 2026-10-26)
- Start date: 2012-06 (registry gives no type) (ClinicalTrials.gov record NCT01609582, source copy `cardio:ctgov-nct01609582-2015-10-19`, retrieved 2026-10-26)
- Primary completion: 2014-05 (actual) (ClinicalTrials.gov record NCT01609582, source copy `cardio:ctgov-nct01609582-2015-10-19`, retrieved 2026-10-26)
- Completion: 2014-05 (actual) (ClinicalTrials.gov record NCT01609582, source copy `cardio:ctgov-nct01609582-2015-10-19`, retrieved 2026-10-26)
- Results first posted: 2015-08-21 (ClinicalTrials.gov record NCT01609582, source copy `cardio:ctgov-nct01609582-2015-10-19`, retrieved 2026-10-26)
- Countries: United States; Argentina; Australia; Brazil; Bulgaria; Canada; Croatia; Czechia; Estonia; France; Germany; Hong Kong SAR China; Hungary; Israel; Italy; Latvia; Lithuania; Malaysia; Mexico; New Zealand; Peru; Philippines; Poland; Romania; Russia; Slovakia; South Africa; South Korea; Taiwan; Thailand; Ukraine; United Kingdom (ClinicalTrials.gov record NCT01609582, source copy `cardio:ctgov-nct01609582-2015-10-19`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "TERMINATED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01609582-2015-10-19`, retrieved 2026-10-26)

## The registry's words

- Brief title: Study of TAK-875 in Adults With Type 2 Diabetes and Cardiovascular Disease or Risk Factors for Cardiovascular Disease
- Condition: Type 2 Diabetes
- Condition: Cardiovascular Disease
- Intervention (Drug): TAK-875
- Intervention (Drug): TAK-875 Placebo
- Lead sponsor: Takeda
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry lists this organization as the lead sponsor: Takeda (`cardio:org-takeda`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Fasiglifam-Induced Liver Injury in Patients With Type 2 Diabetes: Results of a Randomized Controlled Cardiovascular Outcomes Safety Trial (`cardio:pubmed-30459247`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 25198101db359c95f8f7706c46d5665ee88f70644e698a0e1965240ab9e5f068
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
